Modelling the effect of conjugate vaccines in pneumococcal disease: Cohort or population models?

Vaccine

Volumn 28, Issue SUPPL. 6, 2010, Pages

  Standaert, Baudouin ^a   Demarteau, Nadia ^a   Talbird, Sandra ^b   Mauskopf, Josephine ^b  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cohort model; Pneumococcal vaccine; Population model

Indexed keywords

PNEUMOCOCCUS HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTEREMIA; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; HUMAN; MENINGITIS; MEXICO; OTITIS MEDIA; PNEUMOCOCCAL INFECTION; PNEUMONIA; POPULATION MODEL; PRIORITY JOURNAL; STEADY STATE; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; MEXICO; MIDDLE AGED; MODELS, STATISTICAL; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; YOUNG ADULT;

EID: 78249257584     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.015     Document Type: Article

References (20)

1. Ehreth J. The global value of vaccination. Vaccine 2003, 21(January (7-8)):596-600.
2. Weinstein M.C., O'Brien B., Hornberger J., Jackson J., Johannesson M., McCabe C., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 2003, 6(January (1)):9-17.
3. Weinstein M.C. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006, 24(11):1043-1053.
4. Sun X., Faunce T. Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ 2008, 9(November (4)):313-323.
5. De Wals P., Black S., Borrow R., Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin Ther 2009, 31(October (10)):2152-2169.
6. Dewilde S., Anderson R. The cost-effectiveness of screening programs using single and multiple birth cohort simulations: a comparison using a model of cervical cancer. Med Decis Making 2004, 24(September (5)):486-492.
7. Renshaw E. Modeling biological populations in space and time 1991, Cambridge University Press, Cambridge, UK.
8. Clarke S.C. Control of pneumococcal disease in the United Kingdom--the start of a new era. J Med Microbiol 2006, 55(August (Pt 8)):975-980.
9. Melegaro A., Edmunds W.J., Pebody R., Miller E., George R. The current burden of pneumococcal disease in England and Wales. J Infect 2006, 52(January (1)):37-48.
10. McIntosh E.D., Fritzell B., Fletcher M.A. Burden of paediatric invasive pneumococcal disease in Europe, 2005. Epidemiol Infect 2007, 135(May (4)):644-656.
11. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsene J.P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(Apr (4 Suppl.)):S66-S76.
12. Beutels P., Thiry N., Van D.P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25(February (8)):1355-1367.
13. Talbird S., Ismaila A., Taylor T. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine 2010, 28(Suppl. 6):G3-G13.
14. De Wals P., Poirier B., Petit G., Erickson L.J., Pépin J., Black S. Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines. Poster presented at the 2nd Vaccine Global Congress 2008.
15. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54(September (36)):893-897.
16. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57(February (6)):144-148.
17. Bauch C.T., Anonychuk A.M., Van E.T., Pham B.Z., Merid M.F. Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 2009, 29(September (5)):557-569.
18. Mauskopf J. Prevalence-based economic evaluation. Value Health 1998, 1(November (4)):251-259.
19. Mauskopf J. Meeting the NICE requirements: a Markov model approach. Value Health 2000, 3(July (4)):287-293.
20. Mexican Institute of Social Security (IMSS). Directorate of Health Information. Database on dynamic cube format [updated 2008] Available from: http://sinais.salud.gob.mx/basesdedatos/.